Please ensure Javascript is enabled for purposes of website accessibility

Why SmileDirectClub, Avaya Holdings, and Sarepta Therapeutics Jumped Today

By Dan Caplinger - Oct 4, 2019 at 4:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out which of these stocks rose following a big strategic move.

Friday was a good day on Wall Street, as major benchmarks regained some of the ground they had lost earlier in the week. A solid employment report for September helped to allay fears that a recession might be imminent for the U.S., and investors seemed to feel more comfortable about the long-term prospects for key sectors of the market. Some individual stocks saw strong gains. SmileDirectClub (SDC 23.12%), Avaya Holdings (AVYA 5.48%), and Sarepta Therapeutics (SRPT 0.04%) were among the top performers. Here's why they did so well.

SmileDirectClub puts a smile on shareholders' faces

Shares of SmileDirectClub climbed 7.5% despite getting criticism from a short-selling research company. Hindenburg Research asserted that the dental alignment specialist could see its stock fall as much as 85%, and made several inflammatory claims about SmileDirectClub's business. The tooth-aligner maker issued a statement rebutting the allegations and arguing that it's the victim of a campaign to try to prevent competition from what it terms "SmileDirectClub's disruptive business model." The stock initially fell on the report, but the company's quick and forceful response gave investors more confidence.

Person holding a clear aligner near teeth.

Image source: Getty Images.

Avaya finds a partner

Avaya Holdings saw its stock soar 31% after it announced a key partnership. The office communications company said that it would work with RingCentral to offer a new cloud-based communications platform for its clients. Under the deal, RingCentral will be Avaya's exclusive source for unified communications as a service, and RingCentral will make a $125 million preferred equity investment along with advancing $375 million more for future payments and licensing rights. For Avaya, the deal provides valuable cash to help it manage its debt and buy back stock, and investors were pleased at the long-term strategic value of the partnership as well.

Sarepta sees good results

Finally, shares of Sarepta Therapeutics finished higher by 8.5%. The gene therapy specialist said that its SRP-9003 investigational therapy showed promising results in a clinical trial of muscular dystrophy patients. The findings included improved physical function for the three participants in the survey, along with reductions in creatine kinase levels and an encouraging safety profile. The news was especially welcome after some of the challenges that Sarepta has seen with other drugs lately, but it'll still be a long time before SRP-9003 progresses enough to draw realistic conclusions about its long-term prospects.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$109.04 (0.04%) $0.04
Avaya Holdings Corp. Stock Quote
Avaya Holdings Corp.
$0.69 (5.48%) $0.04
SmileDirectClub, Inc. Stock Quote
SmileDirectClub, Inc.
$2.13 (23.12%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.